Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets

Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.

Mosquito — Takeda says dengue was one of the WHO’s top 10 threats to global health in 2019 • Source: Shutterstock: frank60

Qdenga, the dengue vaccine from Takeda Pharmaceutical, which was the first product to test drive the European Medicines Agency’s parallel review route for EU and non-EU markets, is up for opinion by the agency on whether it should be approved.

The EMA is due to adopt a decision on the vaccine this week, around two and a half years after...